The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy
Open accessAbstract
OBJECTIVE: To assess the current use of glucocorticoids (GCs) in Duchenne muscular dystrophy in the UK, and compare the benefits and the adverse events of daily versus intermittent prednisolone regimens. DESIGN: A prospective longitudinal observational study across 17 neuromuscular centres in the UK of 360 boys aged 3-15 years with confirmed Duchenne muscular dystrophy who were treated with daily or intermittent (10 days on/10 days off) prednisolone for a mean duration of treatment of 4 years. RESULTS: The median loss of ambulation was 12 years in intermittent and 14.5 years in daily treatment; the HR for intermittent treatment was 1.57 (95% CI 0.87 to 2.82). A fitted multilevel model comparing the intermittent and daily regiments for the NorthStar Ambulatory Assessment demonstrated a divergence after 7 years of age, with boys on an intermittent regimen declining faster (p<0.001). Moderate to severe side effects were more commonly reported and observed in the daily regimen, including Cushingoid features, adverse behavioural events and hypertension. Body mass index mean z score was higher in the daily regimen (1.99, 95% CI 1.79 to 2.19) than in the intermittent regimen (1.51, 95% CI 1.27 to 1.75). Height restriction was more severe in the daily regimen (mean z score -1.77, 95% CI -1.79 to -2.19) than in the intermittent regimen (mean z score -0.70, 95% CI -0.90 to -0.49). CONCLUSIONS: Our study provides a framework for providing information to patients with Duchenne muscular dystrophy and their families when introducing GC therapy. The study also highlights the importance of collecting longitudinal natural history data on patients treated according to standardised protocols, and clearly identifies the benefits and the side-effect profile of two treatment regimens, which will help with informed choices and implementation of targeted surveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792
A comparison of observational studies and randomized, controlled trials.
Benson, K., & Hartz, A. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422506 · Cited by 2,347
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
Self-citationEmery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Why we need observational studies to evaluate the effectiveness of health care
Black, N. (1996) · BMJ · doi:10.1136/bmj.312.7040.1215 · Cited by 1,598
Population frequencies of inherited neuromuscular diseases—A world survey
Emery, A. E. H. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90039-u · Cited by 1,448
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70272-8 · Cited by 1,172
Self-citationCirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Self-citationGlucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A., Kuntzer, T., Pike, M., & Swan, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub2 · Cited by 539
Self-citationWhen are observational studies as credible as randomised trials?
Vandenbroucke, J. P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16261-2 · Cited by 538
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Biggar, W. D., Harris, V. A., Eliasoph, L., & Alman, B. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.01.010 · Cited by 371
Bone Mineral Density and Fractures in Boys with Duchenne Muscular Dystrophy
Larson, C. M., & Henderson, R. C. (2000) · Journal of Pediatric Orthopaedics · doi:10.1097/01241398-200001000-00016 · Cited by 308
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
King, W. M., Ruttencutter, R., Nagaraja, H. N., Matkovic, V., Landoll, J., Hoyle, C., Mendell, J. R., & Kissel, J. T. (2007) · Neurology · doi:10.1212/01.wnl.0000260974.41514.83 · Cited by 283
Griggs, R. C. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530160047012 · Cited by 279
Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy
Fenichel, G. M., Florence, J. M., Pestronk, A., Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Miller, J. P., Robison, J., King, W., et al. (1991) · Neurology · doi:10.1212/wnl.41.12.1874 · Cited by 263
Reliability of the North Star Ambulatory Assessment in a multicentric setting
Mazzone, E. S., Messina, S., Vasco, G., Main, M., Eagle, M., D’Amico, A., Doglio, L., Politano, L., Cavallaro, F., Frosini, S., et al. (2009) · Neuromuscular Disorders · doi:10.1016/j.nmd.2009.06.368 · Cited by 231
Self-citationBonifati, M. D., Ruzza, G., Bonometto, P., Berardinelli, A., Gorni, K., Orcesi, S., Lanzi, G., & Angelini, C. (2000) · Muscle & Nerve · doi:10.1002/1097-4598(200009)23:9<1344::aid-mus4>3.0.co;2-f · Cited by 231
Mazzone, E., Martinelli, D., Berardinelli, A., Messina, S., D’Amico, A., Vasco, G., Main, M., Doglio, L., Politano, L., Cavallaro, F., et al. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.06.014 · Cited by 216
Self-citationDevelopment of a Functional Assessment Scale for Ambulatory Boys with Duchenne Muscular Dystrophy
Scott, E., Eagle, M., Mayhew, A., Freeman, J., Main, M., Sheehan, J., Manzur, A., Muntoni, F., & The North Star Clinical Network for Paediatric Neuromuscular Disease (2012) · Physiotherapy Research International · doi:10.1002/pri.520 · Cited by 194
Self-citationFunctional changes in Duchenne muscular dystrophy: A 12-month longitudinal cohort study
Mazzone, E., Vasco, G., Sormani, M. P., Torrente, Y., Berardinelli, A., Messina, S., D'Amico, A., Doglio, L., Politano, L., Cavallaro, F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ab2e · Cited by 177
Tannen, R. L., Weiner, M. G., & Xie, D. (2009) · BMJ · doi:10.1136/bmj.b81 · Cited by 162
In Defense of Pharmacoepidemiology — Embracing the Yin and Yang of Drug Research
Avorn, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp0706892 · Cited by 161
Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy
Escolar, D. M., Hache, L. P., Clemens, P. R., Cnaan, A., McDonald, C. M., Viswanathan, V., Kornberg, A. J., Bertorini, T. E., Nevo, Y., Lotze, T., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318227b164 · Cited by 160
Bushby, K. M. D., Francesco Muntoni, A., Urtizberea, A., Hughes, R. A., & Griggs, R. C. (2004) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.05.006 · Cited by 149
Self-citationMayhew, A. G., Cano, S., Scott, E., Eagle, M., Bushby, K., & Muntoni, F. (2011) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2011.03939.x · Cited by 138
Self-citationGrowth monitoring with the British 1990 growth reference
Cole, T. J. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.76.1.47 · Cited by 128
Early corticosteroid treatment in 4 duchenne muscular dystrophy patients: 14‐year follow‐up
Merlini, L., Gennari, M., Malaspina, E., Cecconi, I., Armaroli, A., Gnudi, S., Talim, B., Ferlini, A., Cicognani, A., & Franzonı, E. (2012) · Muscle & Nerve · doi:10.1002/mus.23272 · Cited by 119
Intermittent Prednisone Therapy in Duchenne Muscular Dystrophy: A Randomized Controlled Trial
Beenakker, E. A. C., Fock, J. M., Tol, M. J. V., Maurits, N. M., Koopman, H. M., Brouwer, O. F., & van der Hoeven, J. H. (2005) · Archives of Neurology · doi:10.1001/archneur.62.1.128 · Cited by 100
Endocrine Aspects of Duchenne Muscular Dystrophy
Bianchi, M. L., Biggar, D., Bushby, K. M. D., Rogol, A. D., Rutter, M. M., & Tseng, B. S. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.02.006 · Cited by 80
Self-citationPrednisolone‐induced changes in dystrophic skeletal muscle
Fisher, I. B., Abraham, D., Bouri, K., Hoffman, E. P., Muntoni, F., & Morgan, J. E. (2005) · The FASEB Journal · doi:10.1096/fj.04-2511fje · Cited by 79
Self-citationPrednisone in Duchenne dystrophy
Dubowitz, V. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90019-o · Cited by 77
Drousiotou, A., Ioannou, P. A., Georgiou, T., Mavrikiou, E., CHRISTOPOULOS, G., KYRIAKIDES, T., VOYASIANOS, M., ARGYRIOU, A., & Middleton, L. T. (1998) · Genetic Testing · doi:10.1089/gte.1998.2.55 · Cited by 75
Quinlivan, R. C. M., Shaw, N., & Bushby, K. M. D. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.07.272 · Cited by 49
Self-citationCorticosteroids and duchenne muscular dystrophy: Does earlier treatment really matter?
McDonald, C. M., Han, J. J., Mah, J. K., & Carter, G. T. (2012) · Muscle & Nerve · doi:10.1002/mus.23304 · Cited by 19
Weekend high-dosage prednisone
Moxley, R. T., & Pandya, S. (2011) · Neurology · doi:10.1212/wnl.0b013e318227b272 · Cited by 10
Cited by
Duan, D., Goemans, N., Takeda, S., Mercuri, E., & Aartsma-Rus, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00248-3 · Cited by 1,312
Corticosteroids for the treatment of Duchenne muscular dystrophy
Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., & Manzur, A. Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub4 · Cited by 493
Self-citationMendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1484 · Cited by 405
Gloss, D., Moxley, R. T., Ashwal, S., & Oskoui, M. (2016) · Neurology · doi:10.1212/wnl.0000000000002337 · Cited by 258
RetractedBencze, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010362 · Cited by 20
“GCs, by intermittent and daily intake, are so far the only pharmacological treatment which provide significant improvement in skeletal muscle weakness and slows down the course of pathogenesis [53].”
Background
Metadata
- Authors
- Ricotti, V., Ridout, D. A., Scott, E., Quinlivan, R., Robb, S. A., Manzur, A. Y., Muntoni, F., on behalf of the NorthStar Clinical Network, Manzur, A., Muntoni, F., Robb, S., Quinlivan, R., Ricotti, V., Main, M., Dubowitz Neuromuscular Centre, G. O. S. H. F. C. N. T., Bushby, K., Straub, V., Sarkozy, A., Guglieri, M., Strehle, E., Eagle, M., Mayhew, A., Roper, H., McMurchie, H., Childs, A., Pysden, K., Pallant, L., Spinty, S., Peachey, G., Shillington, A., Wraige, E., Jungbluth, H., Sheehan, J., Spahr, R., Hughes, I., Bateman, E., Cammiss, C., Willis, T., Groves, L., Emery, N., Baxter, P., Senior, M., Hartley, L., Parsons, B., Majumdar, A., Jenkins, L., Naismith, K., Keddie, A., Horrocks, I., Di Marco, M., Chow, G., Miah, A., de Goede, C., Thomas, N., Geary, M., Palmer, J., White, C., Greenfield, K., & Scott, E.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2012-12-18
- Volume
- 84
- Issue
- 6
- Pages
- 698-705
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2113949094
- Cited by
- 263
- References
- 36
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.